Skip to main content
SpringerLink
Log in
Book cover

Peroxisome Proliferator-Activated Receptors (PPARs) pp 1–6Cite as

PPARs: History and Advances

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 952))

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the steroid hormone receptor superfamily, discovered in 1990. To date, three PPAR subtypes have been identified; PPARα, PPAR β/δ, and PPARγ. These receptors share a high degree of homology but differ in tissue distribution and ligand specificity. PPARs have been implicated in the etiology as well as treatment of several important diseases and pathological conditions such as diabetes, inflammation, senescence-related diseases, regulation of fertility, and various types of cancer. Consequently, significant efforts to discover novel PPAR roles and delineate molecular mechanisms involved in their activation and repression as well as develop safer and more effective PPAR modulators, as therapeutic agents to treat a myriad of diseases and conditions, are underway. This volume of Methods in Molecular Biology contains details of experimental protocols used in researching these receptors.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Lalwani ND et al (1983) Detection of a nafenopin binding protein in rat liver cytosol associated with induction of peroxisome proliferation by hypolipidemic compounds. Biochem Biophys Res Commun 116:388–393

    Article  PubMed  CAS  Google Scholar 

  2. Lalwani ND et al (1987) Peroxisome proliferator-binding protein: Identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc Natl Acad Sci USA 84:5242–5246

    Article  PubMed  CAS  Google Scholar 

  3. Alvares K et al (1990) Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family. Proc Natl Acad Sci USA 87:5293–5297

    Article  PubMed  CAS  Google Scholar 

  4. Isseman I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650

    Article  Google Scholar 

  5. Gottlicher M et al (1992) Fatty acids activate chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653–4657

    Article  PubMed  CAS  Google Scholar 

  6. Schmidt A et al (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6:1634–1641

    Article  PubMed  CAS  Google Scholar 

  7. Dreyer C et al (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879–887

    Article  PubMed  CAS  Google Scholar 

  8. Berger J, Moller DF (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435

    Article  PubMed  CAS  Google Scholar 

  9. Sher T et al (1993) cDNA cloning, chromosomal mapping and functional characterization of human peroxisome proliferator activated receptor. Biochemistry 32:5598–5604

    Article  PubMed  CAS  Google Scholar 

  10. Yoshikawa T et al (1996) Assignment of the human nuclear hormone receptor, NUC1 (PPAR delta), to chromosome 6p21.1–p21.2. Genomics 35:637–638

    Article  PubMed  CAS  Google Scholar 

  11. Greene ME et al (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4:281–299

    PubMed  CAS  Google Scholar 

  12. Bugge A, Mandrup S (2010) Molecular mechanisms and genome-wide aspects of PPAR subtype transactivation. PPAR Res 2010:169506

    Article  PubMed  Google Scholar 

  13. Kliewer SA et al (1992) Convergence of 9-Cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 358:771–774

    Article  PubMed  CAS  Google Scholar 

  14. Gearing KL et al (1993) Interaction of peroxisome-proliferator-activated receptor and retinoid x-receptor. Proc Natl Acad Sci USA 90:1440–1444

    Article  PubMed  CAS  Google Scholar 

  15. Ijpenberg A et al (1997) Polarity and specific sequence requirements of peroxisome proliferator-activated receptor heterodimer binding to DNA. A functional analysis of the malic enzyme PPAR response element. J Biol Chem 272:20108–20117

    Article  PubMed  CAS  Google Scholar 

  16. Nielsen R et al (2006) Peroxisome proliferator-activated receptor subtype-and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 26:5698–5714

    Article  PubMed  CAS  Google Scholar 

  17. Gulick T et al (1994) The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012–11016

    Article  PubMed  CAS  Google Scholar 

  18. Wang YX et al (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159–170

    Article  PubMed  CAS  Google Scholar 

  19. Mueller E et al (2002) Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 277:41925–41930

    Article  PubMed  CAS  Google Scholar 

  20. Oberkofler H et al (2002) Peroxisome proliferator activated receptor (PPAR) γ coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 277:16750–16757

    Article  PubMed  CAS  Google Scholar 

  21. Racke M, Drew P (2008) PPARs in neuroinflammation. PPAR Res 2008:638356

    Article  PubMed  Google Scholar 

  22. Calkin AC, Thomas MC (2008) PPAR ­agonists and cardiovascular disease in diabetes. PPAR Res 2008:245410

    Article  PubMed  Google Scholar 

  23. Duval C et al (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422–430

    Article  PubMed  CAS  Google Scholar 

  24. Standiford T, Roman J (2007) PPARs in lung biology and disease. PPAR Res 2007:28765

    Article  PubMed  Google Scholar 

  25. Matthiessen MW et al (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 40:198–205

    Article  PubMed  CAS  Google Scholar 

  26. Pathak R et al (2007) Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats. Fundam Clin Pharmacol 21:291–296

    Article  PubMed  CAS  Google Scholar 

  27. Peters JM et al (2008) Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) 115:107–127

    Article  CAS  Google Scholar 

  28. Kim HS et al (2008) Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. Biochem Biophys Res Commun 367:623–629

    Article  PubMed  CAS  Google Scholar 

  29. Masuda K et al (1995) Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30

    Article  PubMed  CAS  Google Scholar 

  30. Han SJ et al (2008) Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm Res 70:165–173

    Article  PubMed  CAS  Google Scholar 

  31. Holloway AC et al (2008) Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes Metab 10:763–771

    Article  PubMed  CAS  Google Scholar 

  32. Tanaka T et al (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci (USA) 100:15924–15929

    Article  CAS  Google Scholar 

  33. Syversen U et al (2009) Different skeletal effects of the peroxisome proliferator activated receptor (PPAR) alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 9:10

    Article  PubMed  Google Scholar 

  34. Still K et al (2008) The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 83:285–292

    Article  PubMed  CAS  Google Scholar 

  35. Braissant O et al (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354–366

    Article  PubMed  CAS  Google Scholar 

  36. Wang YX et al (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2:e294

    Article  PubMed  Google Scholar 

  37. de Lange P et al (2008) Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle. PPAR Res 2008:172676

    Article  PubMed  Google Scholar 

  38. Narkar VA et al (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405–415

    Article  PubMed  CAS  Google Scholar 

  39. Thevis M et al (2010) Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem 396:2479–2491

    Article  PubMed  CAS  Google Scholar 

  40. Youssef J, Badr M (2011) PPARs and cancer: challenges and opportunities. Br J Pharmacol 164:68–82

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Missouri-Kansas City, Kansas City, MO, USA

    Jihan Youssef & Mostafa Z. Badr

Authors
  1. Jihan Youssef
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mostafa Z. Badr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mostafa Z. Badr .

Editor information

Editors and Affiliations

  1. School of Pharmacy, University of Missouri-Kansas City, Charlotte Street 2464, Kansas City, 64108, USA

    Mostafa Z. Badr

  2. School of Pharmacy, University of Missouri-Kansas City, Charlotte Street 2464, Kansas City, 64108, Missouri, USA

    Jihan A. Youssef

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this protocol

Cite this protocol

Youssef, J., Badr, M.Z. (2013). PPARs: History and Advances. In: Badr, M., Youssef, J. (eds) Peroxisome Proliferator-Activated Receptors (PPARs). Methods in Molecular Biology, vol 952. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-155-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-155-4_1

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-154-7

  • Online ISBN: 978-1-62703-155-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation